TY - JOUR
T1 - Chemotherapy-induced exacerbations of thyroid orbitopathy in a patient with B-cell lymphoma
AU - Liu, C
AU - Dalm, V A S H
AU - van Hagen, P M
AU - Croon-de Boer, F
AU - Paridaens, D
PY - 2018/8
Y1 - 2018/8
N2 - A 55-year-old woman with concurrent active thyroid orbitopathy and B-cell lymphoma developed acute exacerbation of thyroid orbitopathy after receiving Rituximab, cyclophosphamide, hydroxydaunorubicin, Prednisone (R-CHOP) chemotherapy, presenting with subtotal loss of vision and severe eyelid edema. Intravenous methylprednisolone was fully effective within several hours. Further exacerbations of her orbitopathy were seen following every subsequent chemotherapeutic treatment, but responded well to oral prednisone. This case shows that thyroid orbitopathy may severely and acutely progress after chemotherapy for concurrent B-cell lymphoma. Clinical awareness of this potential complication may prevent blindness in this rare subset of patients.
AB - A 55-year-old woman with concurrent active thyroid orbitopathy and B-cell lymphoma developed acute exacerbation of thyroid orbitopathy after receiving Rituximab, cyclophosphamide, hydroxydaunorubicin, Prednisone (R-CHOP) chemotherapy, presenting with subtotal loss of vision and severe eyelid edema. Intravenous methylprednisolone was fully effective within several hours. Further exacerbations of her orbitopathy were seen following every subsequent chemotherapeutic treatment, but responded well to oral prednisone. This case shows that thyroid orbitopathy may severely and acutely progress after chemotherapy for concurrent B-cell lymphoma. Clinical awareness of this potential complication may prevent blindness in this rare subset of patients.
KW - Administration, Oral
KW - Antibodies, Monoclonal, Murine-Derived/adverse effects
KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects
KW - Cyclophosphamide/adverse effects
KW - Doxorubicin/adverse effects
KW - Female
KW - Glucocorticoids/therapeutic use
KW - Graves Ophthalmopathy/chemically induced
KW - Humans
KW - Lymphoma, B-Cell/drug therapy
KW - Magnetic Resonance Imaging
KW - Middle Aged
KW - Orbital Diseases/chemically induced
KW - Prednisolone/therapeutic use
KW - Prednisone/adverse effects
KW - Rituximab
KW - Vincristine/adverse effects
U2 - 10.1080/01676830.2017.1423086
DO - 10.1080/01676830.2017.1423086
M3 - Letter
C2 - 29300515
SN - 0167-6830
VL - 37
SP - 299
EP - 302
JO - Orbit (Amsterdam, Netherlands)
JF - Orbit (Amsterdam, Netherlands)
IS - 4
ER -